Product Description
Beclomethasone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. Beclomethasone is a 17alpha-hydroxy steroid that is prednisolone in which the hydrogens at the 9alpha and 16beta positions are substituted by a chlorine and a methyl group, respectively. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Beclomethasone)
Mechanisms of Action: Steroid Receptor Agonist,Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant,Oral,Nasal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Spasm | Asthma | Chickenpox | Measles | Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Seasonal | Spasm | Asthma
Known Adverse Events: Acute Pain | Pain Unspecified | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Candidiasis | Candidiasis, Oral | Asthma | Status Asthmaticus | Rhinitis | Rhinitis, Allergic | Sinusitis | Headache | Epistaxis
Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Bulgaria, Canada, China, Czech Republic, Hungary, Italy, Mexico, Poland, Puerto Rico, Romania, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Colitis, Ulcerative|Spasm
Phase 1: Oral Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRITON | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2026-01-01 |
|
| FORCE2 | P3 |
Completed |
Asthma |
2024-06-12 |
|
| PSC DS BDP-Once 1 | P1 |
Completed |
Oral Ulcer |
2022-04-28 |
28% |
| BeCalCU | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2018-01-05 |